Role of cell cycle regulators in lung carcinogenesis

Cell Adhesion and Migration

Volumn 4, Issue 1, 2010, Pages 114-123

  Eymin, Beatrice ^a,b   Gazzeri, Sylvie ^a,b  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

Cell cycle regulators; Checkpoint; Kinases; Lung cancer; Therapy

Indexed keywords

CYCLINE;

CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; CELL SIZE; DNA INTEGRATION; EPIGENETICS; GENE MUTATION; HUMAN; LUNG CARCINOGENESIS; PROTEIN FUNCTION; REVIEW;

EID: 77449141842     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.1.10977     Document Type: Review

References (120)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246:629-34.
3. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7.
4. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30.
5. Lam EW, La Thangue NB. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol 1994; 6:859-66.
6. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69.
7. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
8. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630-41.
9. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007; 120:2987-96.
10. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265-75.
11. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 2005; 5:42-50.
12. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173:833-7.
13. Tang CJ, Lin CY, Tang TK. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006; 290:398-410.
14. Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004; 59:249-63.
15. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
16. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5:429-40.
17. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
18. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
19. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
20. Yokota J, Mori N, Akiyama T, Shimosato Y, Sugimura T, Terada M. Multiple genetic alterations in smallcell lung carcinoma. Princess Takamatsu Symp 1989; 20:43-8.
21. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241:353-7.
22. Gouyer V, Gazzeri S, Bolon I, Drevet C, Brambilla C, Brambilla E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998; 18:188-96.
23. Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P, et al. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer 1994; 58:818-24.
24. Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, et al. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg 2003; 75:1727-32.
25. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993; 8:1913-9.
26. D'Amico TA, Massey M, Herndon JE, 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999; 117:736-43.
27. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, et al. Mutations in the retinoblastomarelated gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 2000; 60:372-82.
28. Baldi A, Esposito V, De Luca A, Fu Y, Meoli I, Giordano GG, et al. Differential expression of Rb2/ p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 1997; 3:1691-7.
29. Baldi A, Esposito V, De Luca A, Howard CM, Mazzarella G, Baldi F, et al. Differential expression of the retinoblastoma gene family members pRb/p105, p107 and pRb2/p130 in lung cancer. Clin Cancer Res 1996; 2:1239-45.
30. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 1997; 94:6933-8.
31. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55:505-9.
32. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A inactivation in non smallcell lung cancers. Oncogene 1998; 16:497-504.
33. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 1997; 57:1-6.
34. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95:11891-6.
35. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11:3974-86.
36. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998; 75:187-92.
37. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996; 73:294-300.
38. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007; 55:1-14.
39. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5:243-50.
40. Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla C, et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 2003; 9:2195-203.
41. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34:207-18.
42. Wikman H, Nymark P, Vayrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 2005; 42:193-9.
43. Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res 1995; 1:687-90.
44. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 1995; 55:2968-71.
45. Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer 1998; 22:232-40.
46. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56:722-7.
47. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 2004; 54:549-55.
48. Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2 and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55:1448-51.
49. Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, et al. Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer 1996; 65:734-9.
50. Chaussade L, Eymin B, Brambilla E, Gazzeri S. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Oncogene 2001; 20:6587-96.
51. Kawamata N, Miller CW, Koeffler HP. Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in nonsmall cell lung cancers. Mol Carcinog 1995; 14:263-8.
52. Pei XH, Bai F, Smith MD, Xiong Y. p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. Cancer Res 2007; 67:3162-70.
53. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997; 3:1831-5.
54. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20:3865-71.
55. Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004; 57:58-63.
56. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999; 59:684-8.
57. Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001; 34:59-65.
58. Takahashi S, Kamata Y, Tamo W, Koyanagi M, Hatanaka R, Yamada Y, et al. Relationship between postoperative recurrence and expression of cyclin E, p27 and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 2002; 7:349-55.
59. Tsukamoto S, Sugio K, Sakada T, Ushijima C, Yamazaki K, Sugimachi K. Reduced expression of cell cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001; 34:83-90.
60. Ishihara S, Minato K, Hoshino H, Saito R, Hara F, Nakajima T, et al. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer 1999; 26:187-94.
61. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, et al. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998; 58:1042-7.
62. Masuda A, Osada H, Yatabe Y, Kozaki K, Tatematsu Y, Takahashi T, et al. Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am J Pathol 2001; 158:87-96.
63. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclindependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57:3381-5.
64. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161:207-16.
65. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007; 26:6927-36.
66. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119:2546-56.
67. Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004; 12:1087-92.
68. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9:785-97.
69. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20:1678-87.
70. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 2005; 102:9625-30.
71. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-56.
72. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 2007; 13:6938-46.
73. Karakaidos P, Taraviras S, Vassiliou LV, Zacharatos P, Kastrinakis NG, Kougiou D, et al. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1. Am J Pathol 2004; 165:1351-65.
74. Imai MA, Oda Y, Oda M, Nakanishi I, Kawahara E. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J Cancer Res Clin Oncol 2004; 130:320-6.
75. Ried T, Petersen I, Holtgreve-Grez H, Speicher MR, Schrock E, du Manoir S, et al. Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res 1994; 54:1801-6.
76. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999; 401:297-300.
77. Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000; 6:11-6.
78. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000; 60:242-4.
79. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 2007; 104:4089-94.
80. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclindependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61:647-53.
81. Dosaka-Akita H, Hommura F, Mishina T, Ogura S, Shimizu M, Katoh H, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67 and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001; 61:2500-4.
82. Kosacka M, Piesiak P, Porebska I, Korzeniewska A, Dyla T, Jankowska R. Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo 2009; 23:519-25.
83. Cooper WA, Kohonen-Corish MR, McCaughan B, Kennedy C, Sutherland RL, Lee CS. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009; 55:28-36.
84. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153:963-72.
85. Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 1997; 75:1774-8.
86. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15:252-6.
87. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Kimura Y, et al. Clinical implication of cyclin B1 in non-small cell lung cancer. Oncol Rep 2003; 10:1381-6.
88. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60:4000-4.
89. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2003; 2:291-8.
90. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14:543-9.
91. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW, et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005; 37:883-8.
92. Xu HT, Ma L, Qi FJ, Liu Y, Yu JH, Dai SD, et al. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int 2006; 56:375-80.
93. Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 2007; 28:350-5.
94. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005; 93:719-29.
95. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21:7749-63.
96. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006; 5:2905-13.
97. Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int 2006; 56:503-9.
98. Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res 2006; 12:1121-7.
99. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, et al. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003; 24:47-51.
100. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, et al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 2003; 63:7185-9.
101. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75.
102. Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, et al. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res 2006; 66:11062-9.
103. Eymin B, Claverie P, Salon C, Leduc C, Col E, Brambilla E, et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006; 26:4339-50.
104. Raynaud CM, Mercier O, Commo F, Dartevelle P, Gomez-Roca C, de Montpreville V, et al. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. Lung Cancer 2009; 65:144-9.
105. DiTullio RA Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002; 4:998-1002.
106. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007; 28:2082-8.
107. Zhang P, Wang J, Gao W, Yuan BZ, Rogers J, Reed E. CHK2 kinase expression is downregulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004; 3:14.
108. Kim DS, Kim MJ, Lee JY, Lee SM, Choi JE, Lee SY,et al. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features. Lung Cancer 2009; 65:247-50.
109. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, et al. Histological type-selective, tumorpredominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000; 60:4689-92.
110. Gemma A, Seike M, Seike Y, Uematsu K, Hibino S, Kurimoto F, et al. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer 2000; 29:213-8.
111. Nomoto S, Haruki N, Takahashi T, Masuda A, Koshikawa T, Fujii Y, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999; 18:7180-3.
112. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001; 409:355-9.
113. Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003; 160:341-53.
114. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547-66.
115. George SL. Statistical issues in translational cancer research. Clin Cancer Res 2008; 14:5954-8.
116. Kodym E, Kodym R, Reis AE, Habib AA, Story MD, Saha D. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer 2009; 66:37-47.
117. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29-37.
118. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7.
119. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152-9.
120. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008; 68:7466-74.